Amman Pharmaceutical Industries

ammanpharma.com

Amman Pharmaceutical Industries (API) is the first pharmaceutical company in the MENA region to pioneer the production of niche branded generics in the lines of Ophthalmology, Nasals, and Topical Dermatology. After many years of success, API is proud to be a leader in Jordan and the MENA region having expanded into additional therapy areas and production lines which provide more than 150 registered products. The company employs more than 250 employees serving patients in more than 30 countries across the Middle East & Africa & CIS regions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

VIRPAX PHARMACEUTICALS RECAPS MILESTONES AND HIGHLIGHTS PRODUCT PORTFOLIO

Virpax® Pharmaceuticals, Inc. | December 29, 2021

news image

Virpax® Pharmaceuticals, Inc. "Company" achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I believe that Virpax has made significant progress this past year toward our stated goalsThese accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently...

Read More

PHARMACY MARKET

HALOZYME ANNOUNCES POSITIVE CLINICAL DATA OF ITS HIGH-VOLUME AUTO-INJECTOR DEMONSTRATING SUCCESSFUL RAPID SUBCUTANEOUS DRUG DELIVERY

PR Newswire | October 19, 2023

news image

Halozyme Therapeutics, Inc. announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds. In the study, the biologic was delivered with Halozyme's proprietary high-volume auto-injector (HVAI) in healthy volunteers. The injecti...

Read More

Business Insights

TRIASTEK AND SIEMENS ANNOUNCED A STRATEGIC PARTNERSHIP TO ADVANCE THE PHARMACEUTICAL INDUSTRY'S DIGITAL TRANSFORMATION

Triastek, Inc | March 21, 2022

news image

Triastek, Inc. and Siemens Ltd., China, have agreed to collaborate on digital technologies for the worldwide pharmaceutical business. Triastek's industry-leading 3D printing and digital pharmaceutical technologies, combined with Siemens' worldwide experience in automation and digitalization, should result in unique and disruptive pharmaceutical research and production solutions. Pharmaceutical companies have been encouraged to modernize their manufacturing processes by ado...

Read More

Research

DEBIOPHARM INVESTS IN VERISIM LIFE'S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH

Debiopharm International SA | January 11, 2022

news image

Debiopharm a Swiss biopharmaceutical company, announced their co-investment in California-based start-up VeriSIM Life's $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence. VeriSIM Life's computational platform reduces time and cost of drug development as well as reduces the need for animal testing that, in the vast majority of cases, does not translate well to humans. Debiopharm's co-investment in VeriS...

Read More
news image

Pharmacy Market

VIRPAX PHARMACEUTICALS RECAPS MILESTONES AND HIGHLIGHTS PRODUCT PORTFOLIO

Virpax® Pharmaceuticals, Inc. | December 29, 2021

Virpax® Pharmaceuticals, Inc. "Company" achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I believe that Virpax has made significant progress this past year toward our stated goalsThese accomplishments include accelerated development of our existing product candidates, broadening our pipeline of product candidates, and utilizing grants where appropriate. We recently...

Read More
news image

PHARMACY MARKET

HALOZYME ANNOUNCES POSITIVE CLINICAL DATA OF ITS HIGH-VOLUME AUTO-INJECTOR DEMONSTRATING SUCCESSFUL RAPID SUBCUTANEOUS DRUG DELIVERY

PR Newswire | October 19, 2023

Halozyme Therapeutics, Inc. announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE® drug delivery technology, in approximately 30 seconds. In the study, the biologic was delivered with Halozyme's proprietary high-volume auto-injector (HVAI) in healthy volunteers. The injecti...

Read More
news image

Business Insights

TRIASTEK AND SIEMENS ANNOUNCED A STRATEGIC PARTNERSHIP TO ADVANCE THE PHARMACEUTICAL INDUSTRY'S DIGITAL TRANSFORMATION

Triastek, Inc | March 21, 2022

Triastek, Inc. and Siemens Ltd., China, have agreed to collaborate on digital technologies for the worldwide pharmaceutical business. Triastek's industry-leading 3D printing and digital pharmaceutical technologies, combined with Siemens' worldwide experience in automation and digitalization, should result in unique and disruptive pharmaceutical research and production solutions. Pharmaceutical companies have been encouraged to modernize their manufacturing processes by ado...

Read More
news image

Research

DEBIOPHARM INVESTS IN VERISIM LIFE'S $15M SERIES A ROUND TO ADVANCE AI-ENABLED DRUG RESEARCH

Debiopharm International SA | January 11, 2022

Debiopharm a Swiss biopharmaceutical company, announced their co-investment in California-based start-up VeriSIM Life's $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence. VeriSIM Life's computational platform reduces time and cost of drug development as well as reduces the need for animal testing that, in the vast majority of cases, does not translate well to humans. Debiopharm's co-investment in VeriS...

Read More

Resources

resource image

Pharma Tech

ValGenesis e-Logbook

Video

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us